Therapeutic Efficacies of Wujiwan at Different Compatibilities in Treatment of Irritable Bowel Syndrome
10.13422/j.cnki.syfjx.20211301
- VernacularTitle:戊己丸不同配伍方治疗肠易激综合征的比较
- Author:
Ya-jie WANG
1
;
Xi-he CUI
1
;
Ying CHEN
1
;
Yu-jie LI
1
;
Qing YANG
1
;
Xiao-gang WENG
1
;
Yu DONG
2
;
Wei-yan CAI
1
;
Qi LI
1
;
Xiao-xin ZHU
1
Author Information
1. Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Guang'anmen Hospital，China Academy of Chinese Medical Sciences，Beijing 100053，China
- Publication Type:Research Article
- Keywords:
Wujiwan;
compatibility;
irritable bowel syndrome （IBS）;
5-hydroxytryptamine （5-HT）;
mast cell （MC）;
brain-gut peptides
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(13):1-9
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the therapeutic efficacies of Wujiwan at two different compatibilities （No.1 and No.2） on irritable bowel syndrome （IBS） based on neuro-endocrine-immune network， and provide a theoretical basis for the treatment based on syndrome differentiation in traditional Chinese medicine （TCM）. Method:The chronic animal model of IBS with visceral hypersensitivity was established by colon irritation via percutaneous transluminal coronary angioplasty （PTCA） in suckling rats. The animals were randomly divided into a control group， a model group， a dicetel group （0.01 g·kg-1）， low- （0.335 g·kg-1）， medium- （0.67 g·kg-1）， and high-dose （1.34 g·kg-1） No. 1 Wujiwan groups， and low- （0.385 g·kg-1）， medium- （0.77 g·kg-1）， and high-dose （1.54 g·kg-1） No. 2 Wujiwan groups. The thresholds of abdominal elevation and bow back elevation were evaluated to detect the effect of Wujiwan on intestinal sensitivity of IBS. The density of mast cells （MC） in the colonic tissue of model rats was detected by the modified toluidine blue staining method. The concentrations/positive expression of 5-hydroxytryptamine （5-HT）， substance P （SP）， somatostatin （SS）， and vasoactive intestinal peptide （VIP） in the blood/colon tissue were detected by enzyme-linked immunosorbent assay （ELISA） and immunohistochemistry （IHC） assay. Result:There was no significant difference in body weight among different groups. Compared with the control group， the model group exhibited decreased thresholds of abdominal elevation and bow back elevation （P<0.01）， increased density of MCs in the colon tissue （P<0.05）， up-regulated levels of 5-HT， SP， and SS in the blood and colon tissue （P<0.05， P<0.01）， and elevated VIP level in the colon tissue （P<0.05）. Compared with the model group， Wujiwan at different compatibilities could increase the thresholds of abdominal elevation and bow back elevation （P<0.01）， diminish the count of MC in the colon tissue （P<0.05）， and reduce the levels of 5-HT， SP， SS， and VIP （P<0.05）. As demonstrated by the comparison of No. 1 and No. 2 Wujiwan， No. 1 was superior to No. 2 in reducing the concentrations of 5-HT， SP， and SS in the blood， especially in 5-HT （P<0.01）. No significant difference between No. 1 and No. 2 in reducing 5-HT positive expression in the colon tissue was observed. Compared to the No. 1 Wujiwan， No. 2 significantly reduced SP expression， and the intensity and range of SS expression in the colon tissue in the No. 2 groups were smaller than those in the No. 1 groups （P<0.05）. Conclusion:Wujiwan at different compatibilities was capable of improving gastrointestinal hormone disorder of IBS to reduce intestinal sensitivity. In terms of systemic effect， No. 1 was superior to No. 2， while in terms of local effect， No. 2 was advantageous. No. 1 Wujiwan was superior to No. 2 in the effect on intestinal dynamics， while No. 2 had an advantageous effect on intestinal sensation over No. 1.
